Liberum Capital reiterated their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note released on Thursday morning. Liberum Capital currently has a GBX 1,900 ($24.75) target price on the stock.

Other research analysts also recently issued reports about the company. UBS AG set a GBX 1,600 ($20.84) price target on GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Thursday, April 27th. Goldman Sachs Group, Inc. (The) reissued a buy rating and issued a GBX 1,900 ($24.75) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, May 31st. Bryan, Garnier & Co reissued a buy rating and issued a GBX 1,750 ($22.80) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, May 31st. Deutsche Bank AG reissued a hold rating and issued a GBX 1,720 ($22.41) price objective on shares of GlaxoSmithKline plc in a research note on Friday, June 30th. Finally, Jefferies Group LLC lowered their price objective on GlaxoSmithKline plc from GBX 1,850 ($24.10) to GBX 1,800 ($23.45) and set a buy rating for the company in a research note on Thursday, April 20th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. The company has an average rating of Hold and an average price target of GBX 1,734.73 ($22.60).

GlaxoSmithKline plc (GSK) opened at 1526.00 on Thursday. The company’s market capitalization is GBX 74.59 billion. The firm has a 50-day moving average price of GBX 1,638.77 and a 200-day moving average price of GBX 1,627.17. GlaxoSmithKline plc has a 1-year low of GBX 1,446.50 and a 1-year high of GBX 1,745.56.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Rating Reiterated by Liberum Capital” was published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-rating-reiterated-by-liberum-capital/1463349.html.

The company also recently disclosed a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be issued a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.

In related news, insider Patrick Vallance bought 861 shares of the company’s stock in a transaction on Friday, July 14th. The shares were purchased at an average price of GBX 1,618 ($21.08) per share, for a total transaction of £13,930.98 ($18,148.75). Also, insider Manvinder Singh Banga bought 2,267 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were bought at an average price of GBX 1,599 ($20.83) per share, for a total transaction of £36,249.33 ($47,224.24). Over the last three months, insiders have acquired 3,150 shares of company stock valued at $5,054,075.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.